Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2000-01-07
2002-08-20
Ulm, John (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C530S388220
Reexamination Certificate
active
06436400
ABSTRACT:
BACKGROUND OF THE INVENTION
An intriguing question in cell biology relates to the mechanism(s) by which proteases activate cells. In recent years, a subfamily of G protein-coupled receptors capable of mediating cellular signaling in response to proteases has been identified (T. K. H. Vu et al,
Cell
64:1057-68, 1991; U. B. Rasmussen et al.
FEBS Lett
. 288:123-28, 1991; S. Nystedt et al.,
Proc. Natl. Acad. Sci. USA
91:9208-12, 1994; H. Ishihara et al.,
Nature
353:674-77, 1997). Members of this unique G protein-coupled receptor family include protease-activated receptors PAR1, PAR2 and PAR3. These receptors are characterized by a tethered peptide ligand at the extracellular amino terminus that is generated by minor proteolysis.
The first identified member of this family was the thrombin receptor presently designated protease-activated receptor 1 (PAR1). Thrombin cleaves an amino-terminal extracellular extension of PAR1 to create a new amino terminus that functions as a tethered ligand and intramolecularly activates the receptor (T. K. H. Vu et al,
Cell
64:1057-68, 1991). PAR2 mediates signaling following minor proteolysis by trypsin or tryptase, but not thrombin (S. Nystedt et al.,
Proc. Natl. Acad. Sci. USA
91:9208-12, 1994). Knockout of the gene coding for PAR1 provided, definitive evidence for a second thrombin receptor in mouse platelets and for tissue-specific roles for different thrombin receptors (A. Connolly et al.,
Nature
381:516-19, 1996). PAR3 was identified recently as a second thrombin receptor mediates phophatidyl inositol 4,5 diphosphate hydrolysis, and was found to be expressed in a variety of tissues (H. Ishihara et al.,
Nature
353:674-77, 1997). Many other proteases (such as factor VIIa, factor Xa, factor XIIa, protein C, neutrophil cathepsin G, mast cell tryptase, and plasmin) display cellular effects. Therefore, additional members of the PAR family are expected to exist (S. R. Coughlin,
Proc. Natl. Acad. Sci. USA
91:9200-02, 1994; M. Molino et al.,
J. Biol. Chem
. 272:11133-41, 1997).
The present invention provides an additional member of the PAR family, a novel human protease-activated receptor designated PAR4 (alternatively designated ZCHEMR2). The PAR4 polypeptide is an appropriate target for drug screening, and has other uses that should be apparent to those skilled in the art from the teachings herein.
SUMMARY OF THE INVENTION
The present invention provides a novel human protease activated receptor polypeptide and related compositions and methods.
Within one aspect, the present invention provides an isolated polynucleotide encoding a PAR4 polypeptide selected from the group consisting of (a) polynucleotide molecules comprising a nucleotide sequence as shown in SEQ ID NO:1 from nucleotide 176 to nucleotide 1330; (b) allelic variants of (a); (c) orthologs of (a); and (d) degenerate nucleotide sequences of (a), (b) or (c). In one embodiment, the polynucleotide molecules comprise a nucleotide sequence as shown in SEQ ID NO: 1 from nucleotide 227 to nucleotide 1330. In another embodiment, the polynucleotide molecules comprise a nucleotide sequence as shown in SEQ ID NO: 1 from nucleotide 317 to nucleotide 1330.
Within another aspect, the present invention provides an isolated polynucleotide molecule encoding a PAR4 ligand selected from the group consisting of (a) polynucleotide molecules comprising a nucleotide sequence as shown in SEQ ID NO: 1 from nucleotide 317 to nucleotide 409; (b) allelic variants of (a); (c) orthologs of (a); and (d) degenerate nucleotide sequences of (a) (b) or (c).
Within yet another aspect, there is provided an expression vector comprising the following operably linked elements a transcription promoter; a DNA segment selected from the group consisting of (a) polynucleotide molecules comprising a nucleotide sequence as shown in SEQ ID NO:1 from nucleotide 176 to nucleotide 1330; (b) allelic variants of (a); (c) orthologs of (a); and (d) degenerate nucleotide sequences of (a), (b) or (c); and a transcription terminator. The present invention also provides a cultured cell into which has been introduced such expression vector, wherein the cell expresses the PAR4 polypeptide.
Within a further aspect, the invention provides an isolated PAR4 polypeptide selected from the group consisting of (a) polypeptide molecules comprising an amino acid sequence as shown in SEQ ID, NO: 2 from residue 18 (Gly) to residue 385 (Gln); (b) allelic variants of (a); and (c) orthologs of (a), wherein the PAR4 polypeptide is a protease-activated receptor.
The invention further provides an isolated PAR4 ligand selected from the group consisting of (a) polypeptide molecules comprising an amino-acid sequence as shown in SEQ ID NO:2 from residue 48 (Gly) to residue 53 (Val); (b) allelic variants of (a); and (c) orthologs of (a), as well as a pharmaceutical composition comprising purified PAR4 ligand in combination with a pharmaceutically acceptable vehicle. Another aspect of the invention provides an antibody that binds to an epitope of a PAR4 polypeptide.
These and other aspects of the invention will become evident upon reference to the following detailed description of the invention and attached drawings.
REFERENCES:
patent: 5011912 (1991-04-01), Hopp et al.
U.S. application No. 09/032,397, Coughlin et al., filed Feb. 27, 1998.
Vu et al., “Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation,”Cell64:1057-1068, Mar. 22, 1991.
Rasmussen et al., “cDNA cloning and expression of a hamster &agr;-thrombin receptor coupled to Ca2+mobilization,”FEBS Lett. 288:123-128, Aug., 1991.
Nystedt et al., “Molecular cloning of a potential proteinase activated receptor,”Proc. Nat'l Acad. Sci. USA91:9208-9212, Sep. 1994.
Vu et al., “Domains specifying thrombin-receptor interaction,”Nature353:674-677, Oct. 17, 1997.
Connolly et al., “Role of the thrombin receptor in development and evidence for a second receptor,”Nature381:516-519, Jun. 6, 1996.
Coughlin, “Protease activated receptors start a family,”Proc. Nat'l Acad. Sci. USA91:9200-9202, Sep., 1994.
Molino et al., “Endothelial cell thrombin receptors and PAR-2,”J. Biol. Chem.272:11133-11141, Apr. 25, 1997.
Gerszten et al., “Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface,”Nature368:648-651, Apr. 14, 1994.
Ishii et al., “Inhibition of thrombin receptor signaling by a G-protein coupled receptor kinase,”J. Biol. Chem.269:1125-1130, Jan. 14, 1994.
Probst et al., “Sequence alignment of the G-protein coupled receptor superfamily,”DNA Cell Biol.11:1-20, 1997.
Ishihara et al., “Protease-activated receptor 3 is a second thrombin receptor in humans,”Nature386:502-506, Apr. 3, 1997.
EST from Incyte Pharmaceuticals, Inc., 373881.
EST from Incyte Pharmaceuticals, Inc., 2189250.
EST from Incyte Pharmaceuticals, Inc., 2899749.
EST from Incyte Pharmaceuticals, Inc., 3218437.
Foster Donald C.
Presnell Scott R.
Xu Wen-feng
Yee David P.
Jones Phillip B. C.
Ulm John
ZymoGenetics Inc.
LandOfFree
Protease-activated receptor PAR4 ZCHEMR2 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protease-activated receptor PAR4 ZCHEMR2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protease-activated receptor PAR4 ZCHEMR2 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2972087